Creso Pharma
Creso Pharma
(ASX:CPH, FWB:1X8)


Cannabis

Our Entry Price $ Current Price $ Current Return Highest Price $ Highest Return
$ 0.120 $ 0.200 67% $ 0.470 292%


Overview

Creso Pharma (ASX: CPH) utilises pharmaceutical expertise and methodological rigour to develop cannabis and hemp derived therapeutic, nutraceutical and lifestyle products with wide range patient and consumer reach for human and animal health.

In recent months, CPH has secured several purchase orders, with total POs confirmed for delivery in the first half of 2021 totalling over $1M.

The company is growing its revenue profile across a number of regions and expanding its product lines including its flagship cannaQIX® range of products, which should hopefully translate into continued momentum on the sales front.

Share price gains have also been underpinned by significant developments on the regulatory front that are likely to benefit Creso Pharma across key markets such as the US and the European Union.

In particular, US cannabis regulations are expected to open up following the Democratic Party securing the balance of power in the Senate.

The development enhances the potential for the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to be passed in the Senate, a bill which aims to remove cannabis from the US Controlled Substances Act.

Legislation like the MORE Act is expected to encourage private investors and larger corporate entities that have been hesitant to become involved in the US cannabis industry due to federal prohibition.

Creso Pharma is well positioned to capitalise on near term opportunities in the US market, with an established global distribution network that will benefit from the ruling, as well as a leading Canadian subsidiary, Mernova Medicinal Inc. (Mernova), that already has a 24,000 sq ft cannabis growing facility 220 miles from the US border that can service the US and broader markets.



Our Latest Articles on Creso Pharma


Type Date Share Price $ Title
Email 26-Mar-2021 $ 0.205 We Participated in the CPH placement - and so did Billionaire John Hancock
Email 23-Mar-2021 $ 0.220 TRIPLE DOWN ALERT - Plus 6 Hot Stocks
Email 15-Mar-2021 $ 0.220 SURPRISE: We are Now Psychedelics Investors
Article 15-Mar-2021 $ 0.220 CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company
Email 01-Mar-2021 $ 0.205 CPH deliver Financials and Confirms US Cannabis Market Entry
Article 01-Mar-2021 $ 0.205 CPH Confirms US Cannabis Market Entry with Established Partner - US$5M Sales Target
Email 19-Jan-2021 $ 0.240 The CPH Share Price Seems to Have Stabilised – What’s Next?
Article 07-Jan-2021 $ 0.195 Our Stock Picks for 2021
Article 02-Dec-2020 $ 0.046 What’s Happening to the CPH Share Price?
Email 02-Dec-2020 $ 0.046 Short Term Trade Update: What’s Happening to the CPH Share Price?
Article 13-Oct-2020 $ 0.031 Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH
Email 13-Oct-2020 $ 0.035 We are Rolling the Dice on this One…
Article 24-Mar-2020 $ 0.053 Creso’s New Immunity Boosting CBD Hemp Teas Set for Release
Article 11-Mar-2020 $ 0.071 CPH Secures Two Execs from the World’s Largest Cannabis Company
Article 04-Mar-2020 $ 0.082 Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint
Article 11-Feb-2020 $ 0.160 Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release
Article 06-Feb-2020 $ 0.155 CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough
Article 28-Jan-2020 $ 0.175 CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone
Article 21-Jan-2020 $ 0.190 CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs
Article 09-Dec-2019 $ 0.145 CPH Kick Start African Launch - $300k Order Values Confirmed
Article 03-Dec-2019 $ 0.150 Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Market Data


Latest Article

We Participated in the CPH placement - and so did Billionaire John Hancock

We Participated in the CPH placement - and so did Billionaire John Hancock

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.

Related Articles

Thanks for subscribing!

X